AbbVie To Present 13 Absracts In Inflammatory Bowel Diseases At Digestive Disease Week Annual Meeting

AbbVie ABBV announced Thursday it would present 13 abstracts in inflammatory bowel diseases including adult and pediatric Crohn's disease, and ulcerative colitis at the Digestive Disease Week (DDW) Annual Meeting, May 21-24, 2016, in San Diego. Also, AbbVie and Boehringer Ingelheim would present late-breaking data on risankizumab, which was earlier known as BI 655066, an investigational anti-IL-23 monoclonal biologic antibody.

The drug maker said HUMIRA research to be presented at the meeting included the seven-year interim results from the ongoing PYRAMID post-marketing surveillance safety registry, which is evaluating the safety of HUMIRA in patients with moderate to severe Crohn's disease. The company stated that results of a long-term efficacy, as well as, safety analysis of HUMIRA would also be presented.

Chief Medical Officer and VP Development, Rob Scott, commented, "AbbVie is committed to continued research in gastroenterology in order to make a significant impact on the lives of patients who face the burden inflammatory bowel diseases can have each day. As leaders in immunology, we are focused on improving care for people living with these serious and chronic diseases."

AbbVie said second stage results evaluating the safety and efficacy of risankizumab in patients with moderate to severe Crohn's disease would also be presented as a late-breaking abstract on May 24.

The company indicated HUMIRA was one of the most comprehensively studied biologics available with over 19 years of clinical trial experience beginning in rheumatoid arthritis1 and is currently being used to treat over 989,000 patients worldwide.

The stock traded 1.97 percent down on Thursday.